ASHM @ APACC 2017
Bloggers
Mark Rowe |
PostsAPACC 2017—Who attended
At the close of the 2nd Asia Pacific AIDS & Co-infections Conference (APACC) that took place from 1 to 3 June 2017 in Hong Kong, faculty memb
New HIV drugs/regimens
At one particular session of the 2nd Asia Pacific AIDS & Co-infections Conference (APACC) that took place from 1 to 3 June 2
Population-based PrEP implementation in New South Wales, Australia
This session was delivered by Dr. Andrew Grulich (Kirby Institute, Australia).
Dr. Grulich began by stating that, 'We know PrEP works'. He presented
Hep B New Agents
A very brief blog on Hep B treatment and new agents presented by Jürgen Rockstroh
TAF works for Hep B
Here's the data
Can we cure Hep B like He
Adolescents and HIV
These are some stand out points from the presentations at APACC covering issues related to HIV +ve youth.
#1 cause of death in 18-25 age group
APACC conference mood
It is Saturday evening and the conference is over. I have been sitting and reflecting on the experience of the last few days. Our global p
A blog in pictures
A picture paints a thousand words - Dual Drug Therapy.. a blog in pictures (a Plog?)
This is the history of therapies in HIV
3 drugs work, why are
My impressions of the first 24 hours of APACC 2017
Day 1 of APACC 2017
Other bloggers have written eloquently on sessions on day 1 at this meeting so I thought I might report on my impressions on the
APACC Highlights
As the 2nd Asia Pacific AIDS & Co-infections Conference (APACC) draws to a close I am reinvigorated and ready to implement changes in my
PrEP in Asia
The efficacy of the HIV medication Truvada as an HIV prophylaxis is very well established in the sexual health and HIV treatment/prevention world. Tru
Using ICT to reach key populations
Recruiting people into HIV services Panus Na Nakorn The breakout session PA_9 was entitled, 'Innovative HIV testing, prevention and care service deli
The ageing of PLWHIV calls for new models of primary care.
Rajasthan, R, Malaysia ; HIV and ageing Study.
One of the emerging challenges is the ageing cohort of PLWHIV within Australia. Many of these
Managing HIV / HepC; Sofosbuvir / Velpatasvir effective with management well suited to primary care settings.
Doyle,J (session presentation) ; coEC Study
Lu,Y (2 poster presentations) ; ASTRAL-5 Study
This presentation by J Doyle from
Asia-Pacific HIV Clinical Forum: Integrase inhibitors
HIV Forum—31 May 2017 (11am to 6pm)
I would like to present my interpretation of a session at the HIV Clinical Forum (for integrate inhibitors) held
Asia-specific barriers to care
This area was addressed by two speakers, these being Fujie Zhang and Martin Choo. Dr. Zhang is a medical practitioner whilst Mr. Choo is a social scie
APACC 2017—Key note lecture
Where is the epidemic heading?
Chris Beyrer opened the conference with his keynote lecture entitled, HIV/AIDS in the Asia Pacific: Where is the epide
|